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Truncation and acylation were combined to in-
vestigate the broad-spectrum bactericidal and
hemolytic peptide S4(1–15). Substitution of up
to seven residues with dodecanoic acid (C12)
gradually led to specific antipseudomonal ac-
tivity: out of 40 bacterial strains tested in vitro,
C12-S4(8–15) displayed similar minimal inhibi-
tory concentrations (MICs) as S4(1–15) against
Pseudomonas aeruginosa sp. (identical MIC90)
but was practically inactive against most other
bacteria or erythrocytes. Surface plasmon reso-
nance and isothermal titration calorimetry ex-
periments revealed the binding properties of
S4(1–15) to be consistent with its nonselective
activities, while discriminative activities of C12-
S4(8–15) correlated with high binding affinity
to a membrane containing pseudomonal lipo-
polysaccharides and with lower affinities to
membranes containing nonpseudomonal lipo-
polysaccharides or cholesterol. Various mecha-
nistic studies failed to detect significant dif-
ferences in secondary structure, bactericidal
kinetics, or ability to perturb the cytoplasmic
membrane, pointing to a similar mode of action.
INTRODUCTION
Antimicrobial peptides (AMPs) represent a ubiquitous
component of the innate immune system, whose function
includes control of invading pathogens [1–4]. Over the past
20 years, AMPs have been shown to be effective killers
of viruses [5–9], bacteria, fungi [10–12], protozoa [12–16],
and cancer cells [17–19]. Inspection of over 900 known
AMP sequences reveals no consensus motif in terms of
primary or secondary structure, besides amphipathic or-
ganization which seems to accentuate their overall positive
charge and hydrophobicity [4, 20]. These physical proper-
ties represent essential elements in nonspecific interac-
tions with multiple targets [21], although various fine details
of the mode(s) of action are yet to be fully understood.Chemistry & Biology 14, 7AMPs’ main target is often cited to be the plasma mem-
brane, though recent studies suggest intracellular targets,
at least for some peptides [22–24]. The molecular basis for
peptide specificity is presumably linked to differences in
membrane composition between target and nontarget
cells such as charge density, membrane fluidity [25, 26],
and transmembrane potential [27]. Whichever mechanism
is used by an AMP, its interaction with surface compo-
nents (cell wall or plasma membrane) is likely to play a
major role in antimicrobial or cytolytic actions. Accord-
ingly, AMPs were proposed to induce their effect(s) via
disruption of the cell membrane [28–30] and/or cytoplas-
mic translocation followed by interaction with various
anionic elements [22]. Such nonspecific mechanisms are
likely to inhibit the innate talents of bacteria to develop
resistance [31, 32] and, because of this, AMPs present
an obvious advantage over conventional antibiotics.
Due to their simple structure and broad-spectrum activ-
ity, AMPs represent exquisite candidates for various anti-
microbial applications [33, 34]. However, although various
topical applications are considered [31, 34, 35], they noto-
riously lack adequate specificity, while their relative toxic-
ity toward red blood cells limits their potential systemic
use. Another significant and prohibitive factor is their
relatively high cost, at least as long as they are produced
by chemical synthesis. Thus, new strategies are needed to
reduce toxicity and cost.
Dermaseptins are a large family of 24–34 residue long
linear AMPs [13, 15, 36–41] whose cytolytic properties
are triggered after interaction of N-terminal residues
with the plasma membrane [42, 43]. N-terminal acylation
of dermaseptin S4 derivatives was shown to increase
antimicrobial activity but hemolytic activity was found
to increase as well, especially when using long-chain
hydrophobic acyls [13, 36, 44]. Similar results were ob-
tained with other AMPs [13, 36, 45]. To circumvent the
risk of excessive hydrophobicity of acyl-conjugated
peptides, we attempted in this study to limit hydrophobic-
ity increase by exchanging the hydrophobic N-terminal
amino acid residues by a fatty acid of moderate length
(dodecanoic acid). This strategy was inspired by results
obtained in previous investigations: truncation of three to
four residues from the N terminus of the active sequence
of various AMPs significantly hampered antimicrobial ac-
tivity [41, 46, 47]; C-terminal truncation resulted in active5–85, January 2007 ª2007 Elsevier Ltd All rights reserved 75
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was the shortest derivative having the highest growth
inhibition activity against Escherichia coli [41]. We there-
fore tested the hypothesis that the combination of trunca-
tion and acylation strategies when applied to S4(1–15)
would avoid aggregation in solution and would thereby
enable the assessment of the role of hydrophobicity in
selectivity. Pseudomonas aeruginosa was targeted for its
medical relevance. P. aeruginosa is a clinically common
pathogen due to its natural resistance to many antimicro-
bial agents and plays a major role in lung infections,
namely in cystic fibrosis [48].
RESULTS
Characterization of the Reference Peptide
and Its Derivatives
Initially, antibacterial activity was routinely assessed in
terms of minimal inhibitory concentration (MIC) against
two Gram-positive bacteria (Bacillus cereus and Staphylo-
coccus aureus) and two Gram-negative bacteria (E. coli
and P. aeruginosa), and cytotoxicity toward human red
blood cells (RBCs) was assessed in terms of minimal
concentration that induced 50% hemolysis (LC50). For
comparison purposes, Table 1 also lists the properties of
two antimicrobial peptides that were assessed in human
clinical trials, the magainin derivative (MSI-78) and the
protegrin derivative (IB-367), as well as conventional anti-
biotics (polymixin, rifampin, and piperacillin), which were
all assayed under identical conditions.
Results summarized in Table 1 show that the 15-mer
reference peptide is endowed with large-spectrum anti-
bacterial activity (MIC ranging from 3 to 9 mM) as well as
significant hemolytic activity (LC50 18 mM). Whereas trun-
cation of the N terminus invariably decreased all activities,
dodecanoylation led to heterogeneous consequences:
dodecanoyl substitutions initially resulted in nonselective
antibacterial activities that culminated with C12-S4(5–15).
Beyond the 11-mer derivative, a gradual reversal was
observed where potencies of the shorter acylated deriva-
tives were reduced except against P. aeruginosa, whose
sensitivity was maintained up to the acylated 8-mer deriv-
ative. The potentiating limits of dodecanoylation were
approached with the 7-mer derivative C12-S4(9–15),
which was virtually inactive in all assays. To assess the
specific contribution of the acyl moiety, C12 was replaced
by C14 in S4(8–15) and S4(9–15). The results demonstrate
that increasing only hydrophobicity reverted to nonselec-
tive and hemolytic activities. These results are consistent
with the hypothesis that specificity toward P. aeruginosa
might emerge when an AMP attains a specific set of struc-
tural properties (charge/hydrophobicity?).
S4(1–15) versus C12-S4(8–15)
To delimit mechanistic differences, the peptides were
compared in terms of spectrum of activity, kinetics,
secondary structure, and binding properties, as detailed
below.76 Chemistry & Biology 14, 75–85, January 2007 ª2007 ElsevieAntipseudomonal Activity
Shown in Table 2 are the MIC values obtained in 13 addi-
tional strains of P. aeruginosa. The MIC values for 50%
and 90% of the strains tested (MIC50 and MIC90, respec-
tively) were 3 and 25 mM for the parent peptide, while
C12-S4(8–15) displayed MIC50 and MIC90 values of 12.5
and 25 mM, respectively. This confirmed potency of both
peptides over bacterial species considered extremely
difficult to treat [48, 49]. Discriminative properties were
examined using 23 additional bacterial strains including
various Gram-positive and Gram-negative bacteria (Amer-
ican Type Culture Collection [ATCC] as well as clinical
isolates). As shown in Table 2, all strains tested were
more resistant to C12-S4(8–15).
Bactericidal Kinetics
Bactericidal properties were compared at equal concen-
trations representing 1, 2, and 4 multiples of the MIC value
against a representative strain of P. aeruginosa (ATCC
9027). Figure 1A shows the dose-dependent effect, dem-
onstrating that both peptides have rapid bactericidal
kinetics, namely, both peptides managed to reduce the
colony-forming unit (CFU) count by >6 log units within
15 min of incubation at 4 multiples of the MIC value.
Hemolytic Properties
For comparison purposes, hemolytic properties were
initially assessed in terms of LC50, as listed in Table 2
and in the literature [13–15, 36, 39, 40]. Although these
data indicated that C12-S4(8–15) was less hemolytic
than S4(1–15), the peptide activities were further com-
pared following the recommendations of antibacterial
peptide protocols [50]. Figure 1B compares hemolytic
activity at 60, 120, and 180 mM (concentrations are equal,
respectively, to 10, 20, and 30 multiples of the MIC value
against the reference strain); hemolytic activity was dras-
tically altered. For example, at ten MICs, C12-S4(8–15)
displayed 0.03% hemolysis versus 12.45% for S4(1–15).
Interaction with the Cytoplasmic Membrane
The peptides’ ability to affect bacterial cytoplasmic mem-
brane function was assessed using a membrane-potential-
sensitive fluorescent probe, diSC3-5. Testing P. aerugi-
nosa requires permeabilization of its outer membrane with
EDTA (1 mM). EDTA did not interfere with diSC3-5 fluores-
cence or influence the peptides’ MIC (up to 2 mM EDTA).
Cell viability was monitored by sampling bacteria at vari-
ous time intervals during the diSC3-5 assay and plating
for CFU count. As shown in Figure 2, both peptides caused
rapid (Figure 2A) and dose-dependent (Figure 2B) depolar-
ization of the cytoplasmic membrane. Maximal fluores-
cence did not change after up to 30 min of monitoring (data
not shown). Both peptides displayed faster bactericidal
kinetics (negative cultures were obtained within 5 min) in
the presence of EDTA, probably reflecting facilitated
access of the peptides to the plasma membrane due to
EDTA-mediated destabilization of the outer membrane.
Circular Dichroism
A global indication for structural differences was obtained
using circular dichroism (CD) measurements in PBS in the
presence of POPC:POPG (3:1) liposomes. In PBS alone,
all peptides had an unordered structure (Figure 3). In ther Ltd All rights reserved
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Sequence Designation Hb Qc LC50
d (mM)
MIC (mM)e
Bc Sa Ec Pa
ALWKTLLKKVLKAAAamide S4(1–15)
a 48 5 18 3 9 ± 3 3 6
C12-ALWKTLLKKVLKAAAamide C12-S4(1–15) 75 4 <3 12.5 4.5 ± 1.5 37 ± 13 12.5
LWKTLLKKVLKAAAamide S4(2–15) 47 5 36 4.5 ± 1.5 18 ± 7 4.5 ± 1.5 12.5
C12-LWKTLLKKVLKAAAamide C12-S4(2–15) 69 4 <3 18 ± 7 9 ± 3 25 12.5
WKTLLKKVLKAAAamide S4(3–15) 44 5 >100 >50 >50 37 ± 13 25
C12-WKTLLKKVLKAAAamide C12-S4(3–15) 68 4 <3 18 ± 7 9 ± 3 18 ± 7 12.5
KTLLKKVLKAAAamide S4(4–15) 34 5 >100 >50 >50 >50 >50
C12-KTLLKKVLKAAAamide C12-S4(4–15) 67 4 4 9 ± 3 9 ± 3 9 ± 3 9 ± 3
TLLKKVLKAAAamide S4(5–15) 38 4 >100 >50 >50 >50 >50
C12-TLLKKVLKAAAamide C12-S4(5–15) 72 3 3 4.5 ± 1.5 3 6 6
LLKKVLKAAAamide S4(6–15) 31 4 >100 >50 >50 >50 >50
C12-LLKKVLKAAAamide C12-S4(6–15) 64 3 32 9 ± 3 12.5 12.5 6
LKKVLKAAAamide S4(7–15) 29 4 >100 >50 >50 >50 >50
C12-LKKVLKAAAamide C12-S4(7–15) 61 3 100 12.5 18 ± 7 12.5 6
KKVLKAAAamide S4(8–15) 22 4 >100 >50 >50 >50 >50
C12-KKVLKAAAamide C12-S4(8–15) 55 3 >100 25 25 50 6
KVLKAAAamide S4(9–15) 25 3 >100 >50 >50 >50 >50
C12-KVLKAAAamide C12-S4(9–15) 60 2 >100 >50 >50 >50 50
C14-KKVLKAAAamide C14-S4(8–15) 60 3 22 6 9 ± 3 6 6
C14-KVLKAAAamide C14-S4(9–15) 64 2 27 25 18 ± 7 12.5 25
Reference Antibacterial Compounds
MSI-78 46 10 45 nd 9 ± 3 1.5 1.5
IB-367 45 4 7 nd 3 4.5 ± 1.5 19 ± 6
Polymixin B nd nd nd nd >50 2 0.75
Rifampin nd nd nd nd <0.1 7.5 12.5
Piperacillin nd nd nd nd 50 5.5 12.5
Bc, Bacillus cereus; Sa, Staphylococcus aureus; Ec, Escherichia coli; Pa, Pseudomonas aeruginosa; nd, not determined.
a The reference peptide.
b Hydrophobicity, defined as the percent acetonitrile eluent on a C18 HPLC column.
c Charge at physiological pH.
d Lowest peptide concentration that induced 50% hemolysis (1% RBC) after 3 hr incubation in PBS at 37C.
e Lowest peptide concentration that fully inhibited bacterial growth after 24 hr incubation at 37C. Values represent the mean ± stan-
dard deviation obtained from at least two independent experiments performed in duplicate. Lack of standard deviation reflects
consistency. Decimal values were rounded up to the nearest half-unit for simplicity.presence of liposomes, S4(1–15) displayed a typical
elipticity profile of an a helix as characterized by double
minima at 208 and 222 nm (Figure 3A). Whereas the
truncated derivative S4(8–15), which also did not exhibit
a detectable activity, displayed unordered structure in
both media (Figure 3B), its acylated counterpart C12-
S4(8–15) displayed a reduced yet unambiguous helical
profile (Figure 3C). Consistent with the bioassays, the
shortest derivative tested, C12-S4(9–15), which had weak
antipseudomonal activity, displayed less helicity (Fig-
ure 3D) than C12-S4(8–15).Chemistry & Biology 14,Binding Properties
Binding affinities were determined by both surface
plasmon resonance (SPR) and isothermal titration calo-
rimetry (ITC) using three liposomal preparations whose
compositions mimic bacterial or erythrocyte membranes.
Binding constants are summarized in Table 3. Binding
properties to liposomes whose compositions mimic the
zwitterionic membrane of erythrocytes (POPC:choles-
terol) (9:1) were drastically different between the peptides.
Compared with S4(1–15), the acylated derivative ex-
hibited 60- and 52-fold lower adhesion and insertion75–85, January 2007 ª2007 Elsevier Ltd All rights reserved 77
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Bacteria Strain
S4(1–15) C12-S4(8–15)
MIC (mM)a
Pseudomonas aeruginosa C.I. 12848b 3 25
C.I. 8537 3 25
C.I. 12777 3 25
C.I. 13216 6 25
C.I. 11662 25 25
C.I. 8634 3 25
C.I. 11668 50 12.5
C.I. 11128 25 12.5
C.I. 8732 25 12.5
ATCC 9027 6 6
C.I. 13720 1.5 3
C.I. 12360 0.8 1.5
C.I. 11496 0.4 1.5
C.I. 12459 0.8 1.5
Escherichia coli C.I. 14213 1.5 >50c
C.I. 16328 1.5 >50c
C.I. 16350 1.5 >50c
C.I. 16348 3 >50c
C.I. 16229 1.5 >50
C.I. 14182 3 >50
C.I. 14384 3 >50
C.I. 16233 1.5 >50
C.I. 14517 1.5 >50
C.I. 16377 3 >50
ATCC 35218 3 50
Vibrio cholera Environmental isolate 12.5 >50
Yersinia kristensenii ATCC 33639 6 >50
Salmonella choleraesuis ATCC 7308 6 50
Acinetobacter baumannii ATCC 19606 6 >50
Acinetobacter lwoffii ATCC 15309 6 >50
Enterococcus faecalis ATCC 29212 25 >50
Bacillus cereus ATCC 11778 2 25
Staphylococcus aureus C.I. 15877 25 >50
C.I. 17314 12.5 >50
C.I. 15852 25 >50
C.I. 15916 12.5 >50
C.I. 20745 25 >50
C.I. 15886 6 >50
ATCC 25923 9 25
C.I. 15903 6 2578 Chemistry & Biology 14, 75–85, January 2007 ª2007 Elsevier Ltd All rights reserved
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Hemolytic Activity
(A) P. aeruginosa were exposed to S4(1–15) or
C12-S4(8–15) at different concentrations, sam-
pled after 5, 15, 30, 60, and 120 min, subjected
to serial 10-fold dilutions, and plated on LA
agar dishes for CFU count after overnight incu-
bation. Black, S4(1–15); white, C12-S4(8–15);
squares, circles, and triangles represent 1, 2,
and 4 times the MIC value, respectively; stars,
normal growth in the absence of peptide. Plot-
ted values represent the mean ± standard de-
viation obtained from at least two independent
experiments performed in duplicate.
(B) Peptide hemolytic properties were deter-
mined against washed human erythrocytes
(10% hematocrit) exposed to PBS containing
S4(1–15) or C12-S4(8–15) at 60, 120, and
180 mM (concentrations equal to 10, 20, and 30 multiples of the MIC value, respectively). Hemolytic activity was determined after 1 hr incubation
at 37C by measuring absorbance (405 nm) of the supernatants and comparison with RBCs exposed to PBS containing 0.2% Triton X-100 (for
100% hemolysis) or to PBS alone (for baseline value). S4(1–15), black squares; C12-S4(8–15), white triangles. Statistical data were obtained from
two independent experiments performed in duplicate.affinities, respectively, yielding an overall affinity constant
(Kapparent) that was reduced by three orders of magnitude.
This outcome was consistent with—and may explain—the
observed hemolytic properties.
To assess the possible implication of bacterial outer
membrane lipopolysaccharides (LPS) in peptides’ abilities
to discriminate between E. coli andP. aeruginosa sp., SPR
experiments were conducted using negatively charged
liposomes that incorporated LPS from either E. coli or
P. aeruginosa sp. (Figure 4). Although the two-stage
model may not accurately account for all events in this
somewhat more complex interaction, the SPR data
strongly suggested that C12-S4(8–15) is endowed with
higher (27-fold) binding affinity to P. aeruginosa LPS (Kapp
180 3 104 M1) than to E. coli LPS (Kapp 6.6 3 10
4 M1),
unlike the reference peptide, which displayed 16-fold
higher affinity to E. coli LPS. ITC experiments using liposo-
mal suspensions of the same compositions as in SPR
yielded nearly identical affinity constants (Table 3).
Overall, SPR and ITC data were both consistent with the
biological activities reported in Tables 1 and 2 and support
a role for binding affinities to target cell membranes in
determining the selective activities observed for C12-
S4(8–15).
Peptide Organization in Solution
The light-scattering properties of various derivatives were
investigated in PBS at the relevant (active) concentration
range (data not shown). Whereas C12-S4(1–15) aggre-
gated at low micromolar concentrations, no evidence for
self-assembly could be detected for the substituted
versions, including C12-S4(8–15).Chemistry & Biology 14, 7DISCUSSION
In accordance with the hypothesis that activities of AMPs
proceed by nonspecific mechanisms, we recently verified
that the physicochemical properties of the dermaseptin
derivative S4(1–13) can be exploited to promote signifi-
cant discrimination between Gram-positive and Gram-
negative bacteria [44] by manipulating the hydrophobicity
of its N-terminal sequence. By extending the study, we
show here that physicochemical properties can be
exploited to reduce production costs and to promote
specific antibacterial activity, although it is not clear how
these lipidated peptides would behave in complex
in vivo environments.
To our knowledge, this is the first time it has been shown
that fatty acids can replace peptide sequences. Other
studies have shown the consequences of fatty acid addi-
tion (conjugation) to AMPs [36, 44, 51, 52]. An interesting
comparison can be made with regard to studies showing
that acetylated hexapeptides derived from an 18-mer
AMP maintained antimicrobial activity [51]. However, their
nonselective activity, which was achieved at the cost of
reduced potency [53], was proposed to involve peptide
interaction with an intracellular target [54]. Furthermore,
various optimization studies of either naturally occurring
or de novo designed AMPs indicate that the optimal
molecular length is represented by a 15-mer peptide [36,
41, 55–59]. In this respect, this study establishes that pep-
tide length can be reduced to seven (or fewer) residues by
replacing N-terminal amino acids with a single fatty acid
while preserving the bactericidal mode of action. Sucha Lowest peptide concentration that inhibited bacterial growth by 100% after 24 hr incubation at 37C. Values represent the mean ±
standard deviation obtained from at least two independent experiments performed in duplicate. Lack of standard deviation reflects
consistency.
b Clinical isolates.
c Strain whose MIC was verified to be >500 mM.5–85, January 2007 ª2007 Elsevier Ltd All rights reserved 79
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potency aspects and being more resistant to proteolysis
[36], short acylated peptides represent a considerable
economic gain both because of the number of residues
and because amino acids are considerably more expen-
sive than fatty acids.
Acylation of the truncated peptide promoted selective
activity. Compared with its parent peptide, C12-S4(8–15)
displayed reduced antibacterial activity except against
Figure 2. Cytoplasmic Membrane Depolarization and Viabil-
ity of EDTA-Treated Bacteria
(A) Bacteria (P. aeruginosa ATCC 9027) in mid-logarithmic phase were
permeabilized with EDTA (1 mM), and then diSC3-5 was added (1 mM)
and quenching was allowed to occur at room temperature for 60 min.
KCl (100 mM) was added to equilibrate the cytoplasmic and external
K+ concentrations. Peptides were added to cell suspensions at a con-
centration equal to 4 multiples of the MIC value and changes in fluores-
cence were recorded (excitation and emission wavelengths were
622 nm and 670 nm, respectively). At 0, 5, and 10 min intervals,
aliquots were plated and incubated overnight at 37C to assess cell
viability. Shown are representative fluorescence records of S4(1–15)
(black) and C12-S4(8–15) (gray). Bacterial viability is shown in the
absence of peptide (circles) and in the presence of S4(1–15) (squares)
or C12-S4(8–15) (triangles).
(B) The dose dependence for peptide concentrations equal to 1, 2, and
4 multiples of the MIC value is shown. Plotted values represent the
maximum fluorescence recorded after 30 min exposure to peptides.80 Chemistry & Biology 14, 75–85, January 2007 ª2007 Elseviepseudomonal species. We investigated the possibility
that the derivatives use distinct modes of action:
(1) The peptides displayed similar helical structures.
Moreover, CD data showed a correlation between
active peptides and a-helical structure that was re-
duced or absent in inactive derivatives. Helical struc-
ture is known to stabilize amphipathic organization,
which is critical for activity of many AMPs [46, 60–62]
and of dermaseptins in particular [36, 39, 63]. In the
present case, stabilization is conceivably mediated
by interaction of the acyl chain with the hydrophobic
face of the helix [64].
(2) SPR and ITC data indicated that both derivatives
had lipophilic properties. Incidentally, S4(1–15) was
found to bind better to E. coli LPS and was more active
on most E. coli strains (average MICs are 2.1 versus
10.8, respectively, for E. coli and P. aeruginosa).
(3) Both peptides displayed rapid bactericidal kinetics,
and bacterial death coincided with rapid disruption of
the membrane potential.
Hence, our attempts to detect mechanistic differences
strongly suggest that the peptides essentially use a similar
mechanism of action. The only major difference detected
concerned selectivity, which correlated with loss of two
positive charges and a slight increase in molecular hydro-
phobicity. This resulted in reduced potency over most
bacteria tested but not pseudomonal strains, apparently
due to increased binding affinity mediated by the LPS
component of the outer membrane. As the differences
between these LPS molecules are undetermined, we are
unable to further address this issue at this time. Of course,
tight binding is not the only criterion for more potent
biological function, especially when it comes to a complex
multilevel binding event such as in the present case,
where in order to kill bacteria the AMP is most likely to
sequentially undergo binding events with the outer andFigure 3. Effect of Truncation and
Acylation on the Peptide’s Secondary
Structure
Circular dichroism spectra were measured for
peptide samples (100 mM) that were dissolved
in PBS alone (dashed line) or PBS containing
POPC:POPG (3:1) (solid line). Data represent
average values from three separate record-
ings.
(A) S4(1–15).
(B) S4(8–15).
(C) C12-S4(8–15).
(D) C12-S4(9–15).r Ltd All rights reserved
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POPC:Cholesterol (9:1) POPC:POPG (3:1) + Pa LPS POPC:POPG (3:1) + Ec LPS
S4(1–15) C12-S4(8–15) S4(1–15) C12-S4(8–15) S4(1–15) C12-S4(8–15)
Kadhesion (M
1) 3 104a 79 ± 0.4 1.3 ± 0.8 1.5 ± 0.4 90 ± 0.6 5.6 ± 0.2 7.7 ± 0.1
Kinsertion
a 236 ± 3 4.54 ± 0.02 2.25 ± 0.05 2.0 ± 0.04 10 ± 0.02 0.85 ± 0.03
Kapparent (M
1) 3 104a 1.9 ± 0.4 3 104 5.9 ± 0.7 3.4 ± 0.2 180 ± 0.3 56 ± 0.4 6.6 ± 0.3
K (M1) 3 104b 1.5 ± 0.1 3 104 6.0 ± 0.7 3.2 ± 0.4 140 ± 0.2 58 ± 0.8 6.6 ± 0.3
Chi2 (reflecting the best fit) in both methods ranged between 2.5% and 10%.
Values represent the mean ± standard deviation obtained from two independent experiments.
a SPR affinity constants to each membrane were determined using integrated equations of a two-step model as detailed [38].
b ITC affinity constants to each membrane were determined by integrating enthalpy changes and fitting as described [64].inner membranes plus eventual cytoplasmic components.
In this context, high affinity between the AMP and LPS
may be responsible for efficient recruitment of peptide
Figure 4. Peptide-Binding Properties to Model Membranes
Representative experiments from which were derived the binding pa-
rameters listed in Table 3 are shown in (A) and (B) for S4(1–15) and C12-
S4(8–15), respectively, using SPR (upper panel) and ITC (lower panels).
SPR: shown are binding curves (association/dissociation rates) of five
peptide doses (3, 6, 12, 25, and 50 mM) to a bilayer composed of
POPC:cholesterol (9:1) in PBS (pH 7.4), using the L1 chip. The curves
with greater intensity correspond to higher peptide concentration.
Each sensorgram represents the mean of two different experiments.
ITC: the middle panel is a representative isotherm obtained for titration
of a 12 mM solution with 10 ml of 30 mM POPC:cholesterol (9:1) in PBS
(pH 7.4). The lower panel shows the enthalpy changes for each titration
data point after being integrated and fitted with a one-binding-site
algorithm.Chemistry & Biology 14,molecules. The resulting LPS neutralizing effect of the
initial wave will allow access of additional peptide mole-
cules to inner bacterial targets and induce bacterial death.
This concept is widely supported in the literature [29,
65–67]. Its weakness is indeed the unavailability of data
on the detailed characteristics of peptide-LPS interaction.
Regardless, the novelty of our data is the suggestion that
a specific combination of hydrophobicity, charge, and
secondary structure, such as those found in the lipopep-
tide C12-S4(8–15), is involved in selective antibacterial
activity due to its selective binding to pseudomonal LPS,
albeit activity on Gram-positive bacteria and similar ac-
tivity on certain pseudomonal strains seemingly argue
against the proposed LPS-mediated mechanism of
action. However, as can be seen in Table 2, C12-S4(8–
15) displayed a rather mild potency against only three
out of ten bacteria tested, while in most cases (70%) the
peptide was inactive with MIC > 50 mM. This residual
activity is likely to occur via a different mechanism, as
AMPs are known to target simultaneously multiple sites
of action [21]. Similarly, as LPS varies between strains
(including within the same species), this variation is very
likely to explain the observed potency variations among
pseudomonal strains. The fact remains that compared
with its parent peptide, C12-S4(8–15) displayed reduced
antibacterial activity except against pseudomonal
species.
Acylation of the truncated peptide promoted reduced
hemolysis. Acylation of antimicrobial peptides usually cor-
relates with higher hydrophobic and hemolytic properties
[13, 36, 45, 68]. Therefore, a surprising aspect of this study
relates to the fact that C12-S4(8–15) actually displayed re-
duced hemolysis. The dramatic strong binding of S4(1–15)
to POPC:cholesterol might be of significance and there-
fore deserves full investigation in the future. However,
there are plenty of data in the literature regarding binding
of dermaseptins to erythrocytes and their correlation with
hemolysis [14, 15, 38–41, 69]. Thus, based on the CD and
SPR/ITC data, we propose that the N-terminal sequence
which must be involved in secondary-structure induction
(perhaps consequently) also induces tighter binding to
the cholesterol component of the membrane (compare
secondary structure and hemolysis of S4[1–15] and
S4[8–15]). The fact that despite acylation, which increased
its hydrophobicity, C12-S4(8–15) displayed less structure,75–85, January 2007 ª2007 Elsevier Ltd All rights reserved 81
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supports this hypothesis.
SIGNIFICANCE
Antimicrobial peptides present clear advantages over
conventional antibiotics due to their simple structure,
broad-spectrum rapid lytic activity, and ability to es-
cape resistance. However, they notoriously lack ade-
quate specificity and their toxicity toward red blood
cells limits their potential systemic uses. The present
study provides in vitro evidence in support of the con-
cept that despite their nonspecific mechanism of
action, AMPs’ physicochemical properties can be
exploited to promote discrimination. The data also
suggest that further investigations along the pre-
sented lines of research have the potential to unravel
new, safe, and economical derivatives of known
antimicrobial peptides.
EXPERIMENTAL PROCEDURES
Peptides
The peptides were synthesized by the solid-phase method applying
Fmoc (9-fluorenylmethyloxycarbonyl) active ester chemistry on an
Applied Biosystems model 433A peptide synthesizer (Foster City,
CA, USA) [70]. 4-methylbenzhydrylamine resin (Novabiochem, Darm-
stadt, Germany) was used to obtain amidated peptides. The acylated
analogs were prepared by covalent linking of the peptide amino termi-
nus to lauric acid as described [36]. The crude peptides were purified
to R95% chromatographic homogeneity by reverse-phase high-
performance liquid chromatography (HPLC) (Alliance-Waters, Milford,
MA, USA). Purification and refolding of IB-367, which contains cyste-
ine residues, were performed basically according to the procedure
described by Harwig et al. [71] and repurified by HPLC as described
above; the b-sheet content was confirmed by circular dichroism. The
purified peptides were subjected to amino-acid analysis [72] and elec-
trospray mass spectrometry (Micromass ZQ, Waters) to confirm their
composition and stored as a lyophilized powder at 20C. Prior to
being tested, fresh solutions were prepared in water (10 mM acetate
buffer for IB-367), briefly vortexed, sonicated, centrifuged, and then di-
luted in the appropriate medium. Buffers were prepared with bidistilled
water. Polymixin B, rifampin, and piperacillin were obtained from
Sigma (Jerusalem, Israel). All other reagents were analytical grade.
Bioassays
Growth Inhibition Assay
To assess peptide effect on bacterial proliferation, we used the micro-
dilution susceptibility test [73] as modified [39] to determine the mini-
mal inhibitory concentration (MIC), defined as the lowest peptide
concentration that produced 100% inhibition of growth in overnight
cultures. Briefly, bacterial suspension was grown overnight in Luria
Broth medium (10 g/l trypton, 5 g/l yeast extract, 5 g/l NaCl [pH 7.4])
and diluted to approximately 53 105 bacteria/ml. The cell populations
were estimated by optical density measurements at 620 nm referred to
a calibration curve. One hundred microliters from each dilution were
added to 100 ml of culture medium containing no peptide (control) or
various peptide concentrations (serial 2-fold dilutions) in 96-well plates
(Nunc, Rochester, NY, USA). Inhibition of proliferation was determined
by optical-density measurements after overnight incubation at 37C.
Antibacterial activity was routinely tested against two Gram-positive
bacteria (Bacillus cereus ATCC 11778 and Staphylococcus aureus
ATCC 25923) and two Gram-negative bacteria (Escherichia coli
ATCC 35218 and Pseudomonas aeruginosa ATCC 9027). Further anti-
pseudomonal and specificity tests were performed against 13 clinical82 Chemistry & Biology 14, 75–85, January 2007 ª2007 Elsevieisolates of P. aeruginosa, 10 clinical isolates of E. coli, and 7 clinical
isolates of S. aureus, Salmonella choleraesuis (ATCC 7308), Yersinia
kristensenii (ATCC 33639), Acinetobacter baumannii (ATCC 19606),
Acinetobacter lwoffii (ATCC 15309), Enterococcus faecalis (ATCC
29212), and an environmental isolate of Vibrio cholera. The sources
for pseudomonal clinical isolates listed in Table 2 are urine (ATCC
12848, 13720, 12777, 13216), abscess (ATCC 11668, 8732, 12360),
sputum (ATCC 11496, 11128), catheter (ATCC 11662, 8634), perito-
neal fluid (ATCC 8537), and bronchial wash (ATCC 12459).
Kinetic Studies
Bactericidal kinetics were assessed as described [37]. Briefly, bacte-
rial suspensions of P. aeruginosa were added to culture medium con-
taining 0, 1, 2, or 4 multiples of the MIC value. Bacteria were sampled
after 5, 15, 30, 60, and 120 min exposure to the peptides, subjected to
serial 10-fold dilutions, and plated on Luria Broth agar (LA) dishes for
CFU count after overnight incubation.
Hemolysis
The peptide membranolytic potential as presented in Table 1 was
measured against human red blood cells (RBCs) (1% hematocrit) after
3 hr incubation in PBS at 37C to determine LC50 as described [36].
Alternatively (as specified in the Results and Figure 2), a 10% hemat-
ocrit was used and hemolysis was determined after 1 hr incubation
as described [50].
Cytoplasmic Membrane Permeability Assay
The assay was performed using P. aeruginosa as described [74]. The
lipophilic membrane-potential-sensitive cyanine dye diSC3-5 concen-
trates within cells and self-quenches its own fluorescence. If the tested
compound dissipates the membrane potential, diSC3-5 will be
released into the medium, causing a fluorescence increase. Bacteria
(P. aeruginosa ATCC 9027) in mid-logarithmic phase were suspended
in 5 mM HEPES (pH 7.4) to yield 0.05 optical density at 620 nm. Bac-
terial outer membrane was first permeabilized with EDTA to allow dye
uptake, then diSC3-5 was added (1 mM), and quenching was allowed to
occur at room temperature for 60 min. KCl (100 mM) was then added to
equilibrate the cytoplasmic and external K+ concentrations. Peptides
(1, 2, and 4 multiples of the MIC value) were added to 3 ml bacterial
suspensions, and changes in fluorescence were continuously re-
corded (excitation and emission wavelengths at 622 nm and 670 nm,
respectively). At the specified intervals, aliquots were plated on an
LA plate and incubated overnight at 37C to assess cell viability.
Liposomes
LPS-containing liposomes were prepared as described [75]. Briefly,
a stock solution of LPS (30 mg/ml) in petroleum ether:chloroform:
phenol mixture (8:5:2) is mixed with dried phospholipids (1:1, w/w),
vacuumed overnight, suspended in PBS, heated to 60C, vortexed,
sonicated, and used as stock solution. Large unilamellar vesicles
composed of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine/
1-palmitoyl-2-oleoyl-sn-glycero-3 phosphoglycerol (POPC:POPG,
3:1 molar ratio) or (POPC:cholesterol, 9:1 molar ratio) were prepared
in PBS by the extrusion method as per the manufacturer (Avanti Polar,
Alabaster, AL, USA) instructions using a LiposoFast-Basic extrusion
apparatus (Avestin, Ottawa, ON, Canada) to give a translucent solution
(30 mM) of vesicles with a mean diameter of 100 nm as verified by
dynamic light scattering using a BI-200SM research goniometer
system (Brookhaven Instruments, Holtsville, NY, USA).
Surface Plasmon Resonance
Peptide binding to phospholipid membranes was determined using
the optical biosensor system BIAcore 2000 (Biacore Life Sciences,
Uppsala, Sweden). The experiments, analysis of binding kinetics,
and determination of resulting affinity constants were performed as
described [38]. Experiments were performed in PBS at 30C to enable
comparison with other relevant studies [42, 63].
Isothermal Titration Calorimetry
Experiments were performed using a VP-ITC microcalorimeter (Micro-
cal Origin, Northampton, MA, USA) calibrated electronically. Heats of
dilution were determined in control experiments by injecting either
peptide solution or lipid suspension into buffer. The heats of dilution
were subtracted from the heats determined in the correspondingr Ltd All rights reserved
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with 10 ml injections of 30 mM (based on phospholipids) large unilamel-
lar vesicles in PBS at 30C. Enthalpy changes for each injection were
integrated and fitted using the one-binding-site algorithm (Microcal
Origin, version 5.0).
Circular Dichroism
CD spectra were recorded on a model J-810 spectropolarimeter
(Jasco, Tokyo, Japan) connected to a Jasco spectra manager, using
a QS Hellma quartz cell of 1 mm path length at 25C between 190
and 250 nm at a scanning speed of 50 nm/min. The CD spectrum
was scanned for peptide samples (100 mM) that were dissolved in
sodium phosphate buffer in the presence or absence of liposomes
(2 mM POPC:POPG [3:1]). Minor contributions of circular differential
scattering were eliminated by subtracting the CD spectrum of buffer
and liposomes without peptide. CD data represent average values
from three separate recordings with 1200 scans per sample.
Peptide Self-Assembly
Aggregation properties were investigated by static light-scattering
measurements as detailed [24]. Peptides at an initial concentration
of 50 mM were successively diluted in 2 ml PBS at room temperature
and light scattering was recorded. The static light-scattering signal is
proportional to the number of aggregated molecules and the size of
the aggregate. Therefore the slope is indicative of the aggregation
tendency of the peptides, where a slope value above unity indicates
the presence of a micellar form.
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